Trial Profile
Pioglitazone as a Candidate Chemoprevention Agent for Lung Cancer: A Pilot Trial Using a Pre-surgical Model in Early Stage NSCLC
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 01 Mar 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 25 Jan 2013 New source identified and integrated (Mayo Clinic; 10-006192).
- 14 Sep 2011 Status changed from suspended to recruiting, as reported by ClinicalTrials.gov.